Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bio Farma Launches Pentavalent Vaccine, Combining Five Antigens

Published: Tuesday, August 27, 2013
Last Updated: Tuesday, August 27, 2013
Bookmark and Share
One shot of the vaccine will prevent babies from five diseases at once.

The Indonesian Ministry of Health will introduce a new immunization program, and a pentavalent vaccine for babies aged 2 months to 1 year.

One shot of the pentavalent vaccine will prevent babies from five diseases at once, including Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae Type B.

The pentavalent vaccine, produced by Bio Farma, has been in development since 2007. The product will be launched along with the new immunization program by the Ministry of Health on August 22nd, in Lapangan Karang Pawitan Kabupaten Karawang.

The combination of five antigens is possible due to the similar schedule for 2, 3 & 4 month old babies. With the pentavalent vaccine, babies will require only one shot which contains the five antigens.

Babies are currently given two shots in one period of time, the DTPHB and HIB vaccines. Some babies require three shots, DPT, Hepatitis B and HIB vaccines.

The Production Director of Bio Farma, Juliman, said besides lowering the frequency of babies' shots, the pentavalent vaccine leads to greater efficiencies. "The use of pentavalent vaccine is expected to diminish production costs, cold chain costs, injector costs, and encourage health officers to be efficient. This cost efficiency will translate to affordability for the people."

Juliman added that with the various advantages, the use of pentavalent vaccine is projected to become a future trend for vaccine producers in developing countries.

Juliman spoke during the Global Alliance for Vaccines and Immunization (GAVI), held at Bio Farma on August 21st.

Clinical Trial

Bio Farma has held clinical trials for the pentavalent vaccine since 2010. The vaccine has passed the phase III clinical trial process, ensuring its efficacy for humans.

The trial was conducted with Hasan Sadikin Hospital / Medical Faculty of Padjajaran University and Cipto Mangunkusumo Hospital / Medical Faculty of Indonesian University. Pentavalent has also been registered with the National Agency of Drug & Food Control (NADFC).

"This year we will produce and supply the vaccine to four provinces, West Java, Bali, NTB and Yogyakarta, while later we will be able to produce and fulfill the demand of all provinces of Indonesia," said Juliman.

He predicted that the pentavalent vaccine demand in Indonesia will reach 15 million doses a year, based on the average number of babies' births in Indonesia of 5 million per year.

Besides fulfilling domestic demand, Bio Farma plans to export the vaccine to the other countries after the vaccine passes the WHO prequalification assessment, a requirement for the vaccine to be accepted internationally.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos